Content deleted Content added
Reverting edit(s) by 8.245.8.254 (talk) to rev. 1157779010 by 2A00:23C7:9900:1B01:3113:4C27:E0DA:1D19: likely factual errors (RW 16.1) |
|||
Line 39:
==Products==
Their products are divided into three main categories women's health (27% of revenue), biosimilars (8% of revenue), and established brands (64% of revenue). Women's health products are mainly contraceptives such as ''Nexplanon'', a three year reversible contraceptive implant, and fertility drugs such as ''Puregon'', a follicle-stimulating hormone drug.<ref name="202210k">{{cite report |author= Organon & Co|date=Feburary 22 2023 |title= Organon & Co. |url= https://d18rn0p25nwr6d.cloudfront.net/CIK-0001821825/dbe1f0cc-7777-4da0-8dac-df1f56d85fab.pdf|publisher= SEC |docket= 001-40235 |access-date= September 28 2023}}</ref> Biosimilars provide treatment for oncology and immunology at potentially lower cost than other FDA approved treatments.<ref name=202210k"/><ref><ref name="FDAbiosimilars">{{cite web |title=Biosimilars |url=https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars |website=FDA |publisher=FDA |access-date=30 September 2023}}</ref></ref> Organon makes the biosimilar Hadlima which it compares to [[Humira]]. Their established brands are heavily reliant on sales outside the United States of drugs with generic competition. The cardiovascular products such as Vytorin make a combined 24% of the compnay revenue. <ref name=202210k"/> Revenue figures stated with 2022 figures.
==Research compounds==
| |||